Cymbalta Finds Divergent FDA, European Standards For Fibromyalgia Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The stance of U.S and European regulators on fibromyalgia drug development is diverging, as Lilly has discovered in pursuing a fibromyalgia claim for Cymbalta (duloxetine).